Overview
- Medibyt received FDA 510(k) clearance for CPETWise, enabling U.S. commercialization.
- The platform streamlines cardiopulmonary exercise testing (CPET) analysis, interpretation, and reporting.
- A 100-case University of Washington study reported a >50% reduction in interpretation time.
The News
Medibyt has received FDA 510(k) clearance for CPETWise, an intelligent platform designed to simplify CPET analysis and reporting. The software converts complex physiological data into a standardized workflow while maintaining clinician access to underlying data and interpretations.
The clearance follows a 100-case proof-of-concept study at the University of Washington, where CPETWise achieved an average user satisfaction score of 4.5/5 and reduced interpretation time by more than 50%. Medibyt has also initiated a commercial pilot with a US CPET company and is engaging with global manufacturers to expand adoption.
Industry Perspective
The clearance highlights the potential of automation and machine learning to improve efficiency and standardization in cardiopulmonary diagnostics while supporting clinician-led interpretation.
Strategic Impact
Medibyt plans to expand CPETWise into international markets and broaden its technology into spirometry, BodyBox pulmonary testing, and sports medicine, creating a wider cardiopulmonary diagnostics platform.
Source: PRnewswire
